COVID, myeloma and disability – pro
Unfortunately, there is is not sufficient evidence to state that Stage I myeloma incurs significant risk in regard to COVID-19 or that disability is warranted for someone who is asymptomatic from multiple myeloma. Immune -over-reactivity is an important mechanism in producing COV\FID symptomatology and having some degree of immunodeficiency could theoretically even be protective. In any case, makks and the recommended use of PPR’s very significantly decreased the risk of COVID infections. Without specific evidence of guidelines, R?L cannot be supported in this case, based solely on stage I myeloma diagnosis.
Multiple Myeloma Society says: ” it is not known if people with smoldering myeloma have completely normal immunity or if it is impaired as in active myeloma. It is likely that the majority of smoldering myeloma patients are somewhere between the two extremes. We strongly recommend every individual follow social distancing and good hygiene practices. At this time, there are no specific additional recommendations. “. Stage I myeloma is the first stage down from smoldering myeloma.
Rao, Y., et al., Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis. The Journal of infection, 2020: p. S0163-4453(20)30294-2.
Parri, N., M. Lenge, and D. Buonsenso, Children with Covid-19 in Pediatric Emergency Departments in Italy. New England Journal of Medicine, 2020.
A.J. Barrett, Fighting the flu in multiple myeloma. Volume 117, Issue 1
January 6 2011_
https://themmrf.org/2020/03/05/multiple-myeloma-and-the-coronavirus/. Accessed August 7 2020.